Hot Features
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various me... XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.42735042735 | 2.34 | 2.35 | 2.3 | 42481 | 2.32768836 | CS |
| 4 | -0.11 | -4.50819672131 | 2.44 | 2.4771 | 2.3 | 34339 | 2.35510876 | CS |
| 12 | -0.03 | -1.27118644068 | 2.36 | 2.65 | 2.28 | 28256 | 2.41826382 | CS |
| 26 | -0.12 | -4.89795918367 | 2.45 | 2.7296 | 2.175 | 36458 | 2.42100593 | CS |
| 52 | -0.53 | -18.5314685315 | 2.86 | 3.61 | 2.09 | 56702 | 2.64090901 | CS |
| 156 | -3.63 | -60.9060402685 | 5.96 | 9.96 | 2.09 | 60177 | 4.51769758 | CS |
| 260 | -14.6 | -86.2374483166 | 16.93 | 18.46 | 2.09 | 64673 | 6.19352381 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.